Viridian Therapeutics, Inc./DE Amortization of Debt Issuance Costs
Viridian Therapeutics, Inc./DE (VRDN) reported Amortization of Debt Issuance Costs of $87.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2022-03-11
- Viridian Therapeutics, Inc./DE amortization of debt issuance costs for the quarter ending 2021-12-31 was $87.00K.
- Viridian Therapeutics, Inc./DE amortization of debt issuance costs for the quarter ending 2020-12-31 was $0.00.
- Viridian Therapeutics, Inc./DE amortization of debt issuance costs for the quarter ending 2020-09-30 was $0.00.
- Viridian Therapeutics, Inc./DE amortization of debt issuance costs for the quarter ending 2019-12-31 was $0.00.
- Viridian Therapeutics, Inc./DE amortization of debt issuance costs for fiscal 2021 was $87.00K, a 69.04% decline from fiscal 2020.
- Viridian Therapeutics, Inc./DE amortization of debt issuance costs for fiscal 2020 was $281.00K.
- Viridian Therapeutics, Inc./DE amortization of debt issuance costs for fiscal 2019 was $0.00.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2021-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $87.00K 10-K · filed 2022-03-11 | ||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-05 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | $281.00K 10-K · filed 2022-03-11 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $281.00K 10-Q · filed 2021-11-05 | ||
| 2020-06-30 | $281.00K 10-Q · filed 2020-08-05 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-26 | $0.00 derived: sum of 2 quarters · filed 2021-03-26 | $0.00 10-K · filed 2021-03-26 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |